Abstract
Our report focuses on the case of a pregnant women with recurrent, paranoid schizophrenia. The patient was treated with Olanzapine from the 18th gestational week until delivery and during breast-feeding. No adverse events occurred during pregnancy, and the outcome was healthy. After delivery, the plasma level of olanzapine in the infant was one-third of the maternal plasma level, and during breast-feeding, it decreased to an undetectable limit.
MeSH terms
-
Adult
-
Antipsychotic Agents / adverse effects*
-
Antipsychotic Agents / therapeutic use*
-
Benzodiazepines
-
Breast Feeding
-
Female
-
Humans
-
Infant, Newborn
-
Maternal-Fetal Exchange
-
Olanzapine
-
Pirenzepine / adverse effects
-
Pirenzepine / analogs & derivatives*
-
Pirenzepine / blood
-
Pirenzepine / therapeutic use
-
Pregnancy
-
Pregnancy Outcome*
-
Schizophrenia, Paranoid / drug therapy
Substances
-
Antipsychotic Agents
-
Benzodiazepines
-
Pirenzepine
-
Olanzapine